The earnings call highlighted strong financial performance and strategic growth through successful VYJUVEK launches and R&D progress. However, the anticipated revenue decline in Q3 2025 due to seasonal and patient variability challenges tempers the positive outlook.

Company Guidance -

Q3 2025

During the Krystal Biotech Q2 2025 earnings call, several key metrics and guidance points were highlighted. The company's Q2 net VYJUVEK revenue was reported at $96 million, contributing to a total of over $525 million since its launch. The revenue increase was partly due to patients resuming treatment and the ongoing expansion of the sales team. The gross margin remained consistent at 93%, and the company achieved an EPS of $1.29 per share fully diluted, marking two years of consistently positive earnings per share. Compliance with the drug was reported at 82%, although it is expected to decrease as severe patients achieve durable wound closure. Krystal anticipates 3Q revenues to be lower due to seasonal pausing but expects a return to growth in Q4. The company reported a net income of $38.3 million for the quarter, with over $820 million in cash and investments, positioning it well for upcoming launches in Europe and Japan, and further research and development objectives.

Successful VYJUVEK Launch and Expansion

VYJUVEK net revenue for Q2 2025 was $96 million, bringing total net revenue since launch to over $525 million. The launch in Europe and Japan is expected to further boost growth.

Operational Profitability Maintained

Krystal Biotech reported profitability with $1.29 per share fully diluted for the quarter, marking two years of consistently positive EPS.

Strong Financial Position

The company closed the quarter with over $820 million in cash and investments, supporting upcoming launches and R&D objectives.

Regulatory Approvals in Japan

VYJUVEK received approval from Japan's Ministry of Health, Labour and Welfare with a broad label similar to Europe, facilitating flexible treatment administration.

Progress in Genetic Medicine Pipeline

Significant progress in R&D with multiple ongoing studies in oncology, lung, and eye diseases, including promising data from inhaled KB707 for NSCLC.

Krystal Biotech (KRYS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KRYS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	1.16 / -	0.91	―	―	―
Aug 04, 2025	2025 (Q2)	1.19 / 1.29	0.53	143.40% (+0.76)
May 06, 2025	2025 (Q1)	1.43 / 1.20	0.03	3900.00% (+1.17)
Feb 19, 2025	2024 (Q4)	1.18 / 1.52	0.3	406.67% (+1.22)
Nov 04, 2024	2024 (Q3)	0.99 / 0.91	2.79	-67.38% (-1.88)
Aug 05, 2024	2024 (Q2)	0.73 / 0.53	-1.25	142.40% (+1.78)
May 06, 2024	2024 (Q1)	0.27 / 0.03	-1.76	101.70% (+1.79)
Feb 26, 2024	2023 (Q4)	-0.31 / 0.30	-1.25	124.00% (+1.55)
Nov 06, 2023	2023 (Q3)	-1.20 / 2.79	-1.17	338.46% (+3.96)	―
Aug 07, 2023	2023 (Q2)	-1.26 / -1.25	-1.1	-13.64% (-0.15)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KRYS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$156.98	$134.94	-14.04%
May 06, 2025	$162.29	$139.47	-14.06%
Feb 19, 2025	$156.69	$176.17	+12.43%
Nov 04, 2024	$176.39	$170.85	-3.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Krystal Biotech, Inc. (KRYS) report earnings?

Krystal Biotech, Inc. (KRYS) is schdueled to report earning on Nov 10, 2025, Before Open (Confirmed).

What is Krystal Biotech, Inc. (KRYS) earnings time?

Krystal Biotech, Inc. (KRYS) earnings time is at Nov 10, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KRYS EPS forecast?

KRYS EPS forecast for the fiscal quarter 2025 (Q3) is 1.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing